Arcutis Announces Data from the Phase 2b Study of Topical Roflumilast Cream in Patients with Plaque Psoriasis Selected for La...
04 March 2020 - 12:30AM
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage
biopharmaceutical company focused on developing and commercializing
treatments for unmet needs in immune-mediated dermatological
diseases and conditions, or immuno-dermatology, will showcase data
on its investigational program studying topical roflumilast cream
(ARQ-151) in patients with chronic plaque psoriasis at the 2020
American Academy of Dermatology (AAD) Annual Meeting in Denver, CO,
on March 20-24, 2020.
“We are delighted to participate in the
scientific exchange at this year’s AAD meeting,” said Howard
Welgus, MD, Chief Medical Officer at Arcutis. “Patients and
dermatologists need new and better topical treatment options that
provide improved efficacy, safety and tolerability for patients
with plaque psoriasis. We look forward to sharing data that
demonstrate how topical roflumilast cream could, if approved,
provide a once daily treatment option that effectively addresses
the current challenges of treating plaque psoriasis with topical
therapies."
Title: ARQ-151, Roflumilast
Cream, Significantly Improves Chronic Plaque Psoriasis in Phase 2b
StudySession: S027 - Late-breaking Research:
Clinical TrialsPresenter: Dr. Linda Stein Gold,
Director of Dermatology Clinical Research and Division Head of
Dermatology at the Henry Ford Hospital in Detroit,
MichiganDate: Saturday, March 21, 9:00 – 9:10 a.m.
MTLocation: Bellco Theatre 2
In addition, results from the Phase 1/2a study
of topical roflumilast cream in chronic plaque psoriasis have been
accepted for an e-poster presentation.
Title: ARQ-151, Roflumilast Cream, Improved
Psoriasis in Phase 2a StudyAbstract/poster number:
15309Date: ePosters will be presented Friday,
March 20 - Sunday, March 22, 9 a.m. - 5 p.m. MT
About Topical Roflumilast Cream
(ARQ-151)Topical roflumilast cream (ARQ-151) is a topical
cream formulation containing roflumilast, a PDE4 inhibitor, that
Arcutis is developing to treat plaque psoriasis, including
intertriginous psoriasis, and atopic dermatitis. PDE4 is an
intracellular enzyme that regulates pro-inflammatory and
anti-inflammatory cytokine production and cell proliferation.
Roflumilast was approved by the FDA for systemic treatment to
reduce risk of exacerbation of chronic obstructive pulmonary
disease (COPD) in 2011, and has shown greater potency based on IC50
values (a non-clinical measure of a drug's potency) than other PDE4
inhibitors.
About Arcutis - Bioscience, applied to the
skin.Arcutis is a late-stage biopharmaceutical company focused on
developing and commercializing treatments for unmet needs in
immune-mediated dermatological diseases and conditions, or
immuno-dermatology. Arcutis exploits recent innovations in
inflammation and immunology to develop potential best-in-class
therapies against validated biological targets, leveraging our deep
development, formulation and commercialization expertise to bring
to market novel dermatology treatments, while maximizing our
probability of technical success and financial resources.
Arcutis is currently developing three novel compounds (topical
roflumilast cream (ARQ-151), topical roflumilast foam (ARQ-154) and
ARQ-252) for multiple indications, including psoriasis, atopic
dermatitis, seborrheic dermatitis and eczema. For more information,
please visit www.arcutis.com or follow the Company on LinkedIn.
Contact:John W. SmitherChief Financial
Officerjsmither@arcutis.com
Investors and Media:Heather Rowe ArmstrongVice
President, Investor Relations & Corporate
Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Sep 2023 to Sep 2024